Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laure Fournier Le Ray

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Emerging Infectious Diseases|April 21, 2022
atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment FailureLaure Fournier Le Ray, Alexandra Aubry, Wladimir Sougakoff, et al.
The European Respiratory Journal|May 21, 2020
Fully weekly antituberculosis regimen: a proof-of-concept studyFatma Kort, Laure Fournier Le Ray, Aurélie Chauffour, et al.
Nature Communications|April 7, 2026
Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosisZainab Edoo, Camille Grosse, Thomas Maitre, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Emerging Infectious Diseases|April 21, 2022
atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment FailureLaure Fournier Le Ray, Alexandra Aubry, Wladimir Sougakoff, et al.
The European Respiratory Journal|May 21, 2020
Fully weekly antituberculosis regimen: a proof-of-concept studyFatma Kort, Laure Fournier Le Ray, Aurélie Chauffour, et al.
Nature Communications|April 7, 2026
Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosisZainab Edoo, Camille Grosse, Thomas Maitre, et al.
Pageof 1